BORTEZOMIB, LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE REGIMEN FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND INTRODUCTION OF SERUM FREE LIGHT CHAINS (SFLC) IN RESPONSE MONITORING: PRELIMINARY DATA

被引：0
|
作者：
Pisani, F.
Cordone, I. [1 ]
Dessanti, M. L. [2 ]
Cigliana, G. [1 ]
Frollano, B. [1 ]
Masi, S. [1 ]
Mengarelli, A. [2 ]
Spadea, A. [2 ]
D'Andrea, M. [2 ]
Petti, M. C. [2 ]
机构：
[1] Ist Nazl Tumori Regina Elena, SC Patol Clin, Rome, Italy
[2] Ist Nazl Tumori Regina Elena, SC Ematol, Rome, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [21] Serum free light chains for monitoring multiple myeloma
    Mead, GP
    Carr-Smith, HD
    Drayson, MT
    Morgan, GJ
    Child, JA
    Bradwell, AR
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (03) : 348 - 354
  • [22] A Phase II Study of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone [CDD] for Relapsed or Refractory Multiple Myeloma
    Fiala, Mark
    Keller, Jesse
    Sekhar, Jeevan
    Ceriotti, Connie
    Abboud, Camille
    DiPersio, John
    Tomasson, Michael
    Wildes, Tanya
    Stockerl-Goldstein, Keith
    Vij, Ravi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E56 - E56
  • [23] COMBINATION OF THALIDOMIDE, PEGYLATED LIPOSOMAL DOXORUBICIN, DEXAMETHASONE AND BORTEZOMIB (THADD-V) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: RESULTS OF A PHASE II STUDY
    Offidani, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 153 - 153
  • [24] Final Results of a Phase 1 Study of Vorinostat, Pegylated Liposomal Doxorubicin, and Bortezomib in Relapsed or Refractory Multiple Myeloma
    Voorhees, Peter M.
    Gasparetto, Cristina
    Moore, Dominic T.
    Winans, Diane
    Orlowski, Robert Z.
    Hurd, David D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (07): : 424 - 432
  • [25] Phase I/II study of bortezomib in combination with liposomal doxorubicin and melphalan in relapsed or refractory multiple myeloma.
    Chari, A
    Kaplan, L
    Linker, C
    Damon, LE
    Navarro, WH
    Martin, T
    BLOOD, 2005, 106 (11) : 379B - 379B
  • [26] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Shigeru Kusumoto
    Kazutaka Sunami
    Mitsuo Inagaki
    Shinsuke Iida
    International Journal of Hematology, 2015, 101 : 578 - 584
  • [27] Phase I study of pegylated liposomal doxorubicin in combination with bortezomib for Japanese patients with relapsed or refractory multiple myeloma
    Kusumoto, Shigeru
    Sunami, Kazutaka
    Inagaki, Mitsuo
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 578 - 584
  • [28] EFFICACY OF THE COMBINATION THERAPY OF LIPOSOMAL ADRYAMICIN, BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (ABCD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
    Romano, A.
    Chiarenza, A.
    Gorgone, A.
    Schinocca, L.
    Uccello, G.
    Cavalli, M.
    Fiumara, P.
    Motta, G.
    Palumbo, G.
    Di Raimondo, F.
    HAEMATOLOGICA, 2012, 97 : 607 - 607
  • [29] A 4-Drug, Weekly Combination Regimen of Bortezomib, Cyclophosphamide, Liposomal Doxorubicin, and Dexamethasone for Initial Treatment of Multiple Myeloma
    Becker, Pamela S.
    Gooley, Ted A.
    Lilleby, Kathy
    Green, Damian J.
    Burwick, Nicholas
    Wallace, Christine
    Kim, Theodore
    Kojouri, Kiarash
    Nelli, Erin
    Bensinger, William I.
    BLOOD, 2012, 120 (21)
  • [30] Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma
    Ludwig, Heinz
    Kasparu, Hedwig
    Leitgeb, Clemens
    Rauch, Elisabeth
    Linkesch, Werner
    Zojer, Niklas
    Greil, Richard
    Seebacher, Adelheid
    Pour, Ludek
    Weissmann, Adalbert
    Adam, Zdenek
    BLOOD, 2014, 123 (07) : 985 - 991
12345